<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604811</url>
  </required_header>
  <id_info>
    <org_study_id>P00048 GP 4 03</org_study_id>
    <secondary_id>2011-005307-33</secondary_id>
    <nct_id>NCT01604811</nct_id>
  </id_info>
  <brief_title>Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)</brief_title>
  <acronym>PERMIN</acronym>
  <official_title>Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent
      published works pointed out that urine and serum markers could be used for detection of
      prostatic inflammation.

      The aim of the study is to assess the activity on inflammation biomarkers (serum and urine
      inflammation markers) of Permixon® 160 mg hard capsule and Tamsulosine Arrow LP in the
      treatment of urinary symptoms related to BPH.

      The potential links between serum and urinary markers of inflammation and BPH clinical
      symptoms at baseline and on treatment will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of Inflammation Biomarkers</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>&quot;Inflammation biomarkers assay in patients suffering from Benign Prostatic Hyperplasia at Day 1, Day 30 and Day 90 :
Urine inflammation markers [mRNA (messenger RiboNucleic Acid) and proteins] on the first urine flow after digital rectal examination
Serum inflammation markers (C-Reactive Protein and Sedimentation Rate) &quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of urinary symptoms</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Urinary symptoms assessed by International Prostate Symptom Score (I-PSS) (self-administered questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of quality of life</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Impact of symptoms on quality of life on the basis of the I-PSS quality of life question scored by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of sexual activity</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Sexual activity assessed by the Male Sexual Function questionnaire (MSF-4) (self-administered questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of maximum urinary flow rate</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Uroflowmetry performed using an electronic flow meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of prostate volume</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Prostate volume determined by transrectal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of post-void residual urine volume (PVR)</measure>
    <time_frame>Day 1 (baseline), Day 30, Day 90</time_frame>
    <description>Post-void residual urine volume determined by suprapubic ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Tested product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permixon® 160 mg</intervention_name>
    <description>Oral administration - 160 mg twice daily.</description>
    <arm_group_label>Tested product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosine Arrow LP</intervention_name>
    <description>Oral administration - 0.4 mg daily.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Permixon® 160 mg</intervention_name>
    <description>Oral administration - twice daily.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Tamsulosine Arrow LP</intervention_name>
    <description>Oral administration - daily.</description>
    <arm_group_label>Tested product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patient

          -  Between 45 and 85 years old.

          -  Patient with bothersome lower urinary tract symptoms such as pollakiuria (daytime or
             night time), urgency, sensation of incomplete voiding, delayed urination or weak
             stream, existing for over 12 months

          -  I-PSS ≥ 10 at selection visit and ≥ 12 at randomisation visit (visit 2)

          -  Stable patient's disease at randomisation defined as an absolute difference of 2 or
             less on I-PSS between selection and randomisation visits (visit 1 and visit 2)

          -  I-PSS QoL score ≥ 3 evaluated at selection and randomisation visits,

          -  5 mL/s ≤ maximum urinary flow rate &lt; 15 mL/s for a voided volume ≥ 150 mL and ≤ 500 mL
             evaluated at randomisation visit (2 measurements if necessary)

          -  Prostatic volume ≥30 cm³ determined by transrectal ultrasound at randomisation visit
             (visit 2)

          -  Serum total PSA at randomisation visit (visit 2) :

               -  4 ng/mL

               -  10 ng/mL and Prostate Specific Antigen (free) / Prostate Specific Antigen (total)
                  ≥ 25% or negative prostate biopsy within the past 6 months prior to selection
                  visit.

          -  Patient able to understand and sign the informed consent and understand and fill in
             self-questionnaires

        Exclusion Criteria:

          -  Post-void residual urine volume &gt; 200 mL (by suprapubic ultrasound) at randomisation
             visit (visit 2).

          -  Urological history :

               -  Urethral stricture disease and/or bladder neck disease

               -  Active (at selection and randomisation visits) or recent (&lt; 3 months) or
                  recurrent urinary tract infection

               -  Indication of BPH surgery

               -  Stone in bladder or urethra

               -  Acute or chronic (documented) prostatitis

               -  Prostate and cancer cancer treated or untreated

               -  Interstitial cystitis (documented by symptoms and/or biopsy)

               -  Active upper tract stone disease causing symptoms

          -  Patient with history of surgery of the prostate, bladder neck or pelvic region

          -  Any local and/or systemic inflammation disorders at selection and randomisation visit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Fousseret</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Orens de Gameville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Segre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seysses</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tierce</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>A.Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saw palmetto extract</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

